Arcellx (ACLX) Stock Price, News & Analysis

Company Overview

Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development. Arcellx is advancing lead clinical candidates for relapsed or refractory blood cancers, while exploring applications in solid tumors and autoimmune indications. Manufacturing operations are conducted at the company’s proprietary facility in Malvern, Pennsylvania, with additional process development and scale-up capabilities in the greater Philadelphia region.

Founded in 2018, Arcellx has established collaborations with academic centers and contract research organizations across North America and Europe to support its clinical trial activities. The company is led by an experienced management team with deep expertise in cell therapy research, clinical development and biomanufacturing. Arcellx’s leadership is committed to translating its engineered cell technology into novel treatments that can overcome the limitations of current approaches and address significant unmet medical needs.

Key Stats

• Today's Range: $69.96 to $71.83
• 50-Day Range: $64.69 to $74.08
• 52-Week Range: $47.86 to $107.37
• Volume: 164,397 shs
• Average Volume: 654,145 shs
• Market Capitalization: $3.98 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $114.31
• Consensus Rating: Buy

Arcellx Stock Analysis - MarketRank™

Arcellx scored higher than 44% of companies evaluated by MarketBeat, and ranked 693rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Arcellx has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 13 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arcellx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arcellx are expected to decrease in the coming year, from ($1.58) to ($2.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcellx is -20.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcellx is -20.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcellx has a P/B Ratio of 10.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.74% of the float of Arcellx has been sold short.

Short Interest Ratio / Days to Cover

Arcellx has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcellx does not currently pay a dividend.

Dividend Growth

Arcellx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.74% of the float of Arcellx has been sold short.

Short Interest Ratio / Days to Cover

Arcellx has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.

Change versus previous month

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.49

News Sentiment

Arcellx has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Arcellx this week, compared to 6 articles on an average week.

Search Interest

Only 5 people have searched for ACLX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

MarketBeat Follows

1 people have added Arcellx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $101,040.00 in company stock.

Percentage Held by Insiders

Only 8.35% of the stock of Arcellx is held by insiders.

Percentage Held by Institutions

96.03% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACLX Stock Analysis - Frequently Asked Questions

How have ACLX shares performed this year?

Arcellx's stock was trading at $76.69 at the beginning of the year. Since then, ACLX stock has decreased by 7.7% and is now trading at $70.8050.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) announced its quarterly earnings data on Thursday, August, 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $0.09. The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $16.76 million. Arcellx had a negative trailing twelve-month return on equity of 43.04% and a negative net margin of 329.93%.

When did Arcellx IPO?

Arcellx (ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.

Who are Arcellx's major shareholders?

Arcellx's top institutional shareholders include Vestal Point Capital LP (4.96%), Perceptive Advisors LLC (4.47%), State Street Corp (2.87%) and JPMorgan Chase & Co. (1.77%). Insiders that own company stock include Sr One Capital Management, Llc, Jill Carroll, Rami Elghandour, Christopher Heery, Michelle Gilson, Olivia C Ware, Olivia C Ware and Kavita Patel.
View institutional ownership trends.

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arcellx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcellx investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/04/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACLX
• CIK: 1786205
• Web: arcellx.com
• Phone: 240-327-0603
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Arcellx: $114.31
• High Price Target: $136.00
• Low Price Target: $100.00
• Potential Upside/Downside: +60.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$107.35 million
• Net Margins: -329.93%
• Pretax Margin: -326.84%
• Return on Equity: -43.04%
• Return on Assets: -27.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.81
• Quick Ratio: 3.81

Sales & Book Value

• Annual Sales: $107.94 million
• Price / Sales: 36.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.07 per share
• Price / Book: 10.07

Miscellaneous

• Outstanding Shares: 55,460,000
• Free Float: 50,828,000
• Market Cap: $3.95 billion
• Optionable: Optionable
• Beta: 0.28